inCerebro

inCerebro is a South Korean biopharmaceutical company specializing in quantum mechanics-driven and artificial intelligence-based drug discovery. Founded in 2019 by Dr. Art E. Cho, a former Schrödinger scientist and Korea University professor, the company leverages its proprietary MIND (Modeling with Intelligence for Novel Drugs) platform to identify and optimize small molecule drug candidates. The MIND platform integrates AI with physics-based molecular modeling, specifically utilizing quantum mechanical calculations, QM/MM docking, and water pharmacophore analysis to predict protein-ligand binding with high precision. inCerebro collaborates with major pharmaceutical companies, including SK Chemicals, Samjin Pharm, and KyungDong Pharm, to co-develop novel therapeutics for challenging targets such as GPCRs and kinases in oncology and fibrosis.